Stryker Corporation

New York Stock Exchange
Back to all articles
Bullish +65

Why Stryker Corporation (SYK) is the Best Medical Device Stock to Buy

📈 Stryker Corporation (NYSE: SYK) is ranked ninth on a list of top medical device stocks selected by elite hedge funds based on Q3 2024 sentiment data.

🌍 The global medical devices market is projected to reach $955.49 billion by 2030, growing at a compound annual rate of 6.99% driven by demographic shifts.

🦴 Stryker operates across Neurotechnology, Medical and Surgical, and Orthopedics segments, holding approximately 13,000 global patents to protect its product portfolio.

💰 The company has maintained a streak of paying and raising dividends for 31 consecutive years with annual sales never dropping more than 6% since 1984.

🤖 Record installations were achieved for the Mako robotic-assisted surgery systems in the U.S. and globally during fiscal Q4 2024.

📊 Stryker reported 10% year-over-year organic sales growth for both fiscal Q4 2024 and the full-year 2024.

💹 Adjusted earnings per share increased by 16% year-over-year in fiscal Q4 2024, reflecting strong profitability.

🤝 The company completed seven acquisitions in 2024, including Inari Medical, to strengthen its market position in the peripheral vascular sector.

⭐ Parnassus Core Equity Fund views Stryker as a best-in-class provider with significant revenue and market share growth compared to competitors.

🚀 Upcoming product launches and the expansion of the Mako robotic-assisted surgery arm are cited as key drivers for future optimism.

Bullish Signals
  • Stryker reported 10% year-over-year organic sales growth in both fiscal Q4 2024 and full-year 2024, indicating robust demand for its products.
  • The company achieved a 16% year-over-year increase in adjusted EPS during fiscal Q4 2024, demonstrating strong earnings power.
  • Stryker completed seven acquisitions in 2024, including the purchase of Inari Medical, to expand its footprint in high-growth peripheral vascular markets.
  • The firm holds approximately 13,000 global patents, providing a durable competitive moat against replication by competitors.
  • Stryker has maintained a consistent track record of paying and raising dividends for 31 consecutive years, signaling financial stability.
  • Record installations of the Mako robotic-assisted surgery systems occurred in fiscal Q4 2024, highlighting strong adoption of its innovative technology.
  • Parnassus Core Equity Fund identifies Stryker as a leader in orthopedics with a broad product offering driving significant revenue growth.
Full Analysis
This article evaluates Stryker Corporation (NYSE: SYK) as a top medical device stock, ranking it ninth on a list of elite hedge fund picks. The analysis highlights the broader medical device market's projected growth to $955.49 billion by 2030, driven by an aging global population and technological advancements like AI and robotics. Stryker operates in Neurotechnology, Medical and Surgical, and Orthopedics segments, holding approximately 13,000 patents. The company demonstrated resilience with annual sales never dropping more than 6% historically and a streak of 31 consecutive years of dividend payments. In fiscal Q4 2024, the firm reported record installations for its Mako robotic-assisted surgery systems. Financial performance metrics show strong momentum, with 10% year-over-year organic sales growth in both fiscal Q4 2024 and full-year 2024. Adjusted earnings per share increased by 16% year-over-year in the fourth quarter of 2024. The company also completed seven acquisitions in 2024, including Inari Medical, to expand its presence in the peripheral vascular market. Parnassus Core Equity Fund praises Stryker as a best-in-class provider with dominant orthopedics leadership and optimism regarding upcoming product launches. However, the article concludes by suggesting that AI stocks may offer higher returns in shorter timeframes, though it maintains SYK's strong position within the medical device sector.